What's Happening?
Scientists at the La Jolla Institute for Immunology (LJI) have identified human monoclonal antibodies (mAbs) capable of neutralizing the measles virus (MeV). These antibodies, derived from the memory B immune cells of an individual previously vaccinated
with the MMR vaccine, target the hemagglutinin (H) and fusion (F) proteins of the virus, preventing its entry into host cells. The research, led by Erica Ollmann Saphire, PhD, demonstrated that these antibodies could significantly reduce viral load in a rodent model. The study suggests that these antibodies could serve as both a prophylactic and therapeutic measure against measles, especially important as vaccination rates decline, leading to outbreaks. The antibodies could provide protection for those who cannot receive the live-attenuated measles vaccine, such as individuals with compromised immune systems or infants.
Why It's Important?
The development of these antibodies is crucial as measles outbreaks have increased due to declining vaccination rates. This poses a significant risk to individuals who cannot be vaccinated, such as those with weakened immune systems or young children. The antibodies offer a potential treatment option for these vulnerable groups, providing a means to combat the virus even after exposure. This advancement could help restore community protection, or herd immunity, which has been compromised. The research also highlights the potential for monoclonal antibody therapies to address other infectious diseases, offering a new avenue for medical intervention.
What's Next?
Further research and clinical trials will be necessary to confirm the efficacy and safety of these antibodies in humans. If successful, these antibodies could be developed into a treatment for measles, providing a critical tool in the fight against the virus. The research team plans to explore the use of these antibodies in combination therapies to enhance their effectiveness and prevent viral escape. The findings could also inform the development of similar therapies for other infectious diseases, expanding the potential impact of this research.
